| The Effect of Rituximab, Cyclophosphamide, Vincristine, and Prednisolone (R-CVP) Chemotherapy in Patients with Ocular Adnexal Extranodal Marginal Zone B Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. |
|
Sung Jin Park, Won Sik Lee, Jae Wook Yang |
1Department of Ophthalmology, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea. oculoplasty@gmail.com
2Ocular Neovascular Disease Research Center, Busan, Korea.
3Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea. |
| 안와 부속기 MALT 림프종 환자에서 R-CVP 복합 항암 화학 요법의 치료 효과 |
|
박성진1⋅이원식3⋅양재욱1,2 |
Department of Ophthalmology, Busan Paik Hospital, Inje University College of Medicine1, Busan, Korea
Ocular Neovascular Disease Research Center2, Busan, Korea
Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine3, Busan, Korea |
|
|
| Abstract |
PURPOSE
To report the effectiveness of rituximab, cyclophosphamide, vincristine, and prednisolone (R-CVP) combination chemotherapy in patients with ocular adnexal mucosa-associated lymphoid tissue (MALT) lymphoma (OAML). METHODS: R-CVP chemotherapy was performed in 7 patients (8 eyes) with a confirmed histopathological diagnosis of OAML from January 2012 to December 2012. A total of 6 cycles were administered at a 3-4 week interval and 2 cycles of rituximab were added at the third week. Response evaluation was performed 3 times, with the first evaluation 3 weeks after the third cycle, the second 3 weeks after the sixth cycle, and the last after the second rituximab cycle. RESULTS: In all 7 patients (8 eyes) with R-CVP, symptoms were improved, and the mass was markedly resolved based on orbit CT and MRI scan at first response evaluation. Clinically complete remission (CR) was achieved in 6 patients and partial response (PR) in 1 patient. At final response assessment, there was no detectable mass on orbit CT or MRI. There were no severe infections or hematologic adverse effects including neutropenia or decreased immunoglobulin during the follow-up period. CONCLUSIONS: In OAML, R-CVP combination chemotherapy is considered an effective, safe and important therapeutic approach, reducing the limitations of classic localized radiotherapy and combination chemotherapy and improving the remission rate. |
| Key Words:
Ocular Adnexal MALT Lymphoma;Radiotherapy;R-CVP |
|
PDF Links
Full text via DOI
Download Citation
